<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02923206</url>
  </required_header>
  <id_info>
    <org_study_id>M-2016-313</org_study_id>
    <nct_id>NCT02923206</nct_id>
  </id_info>
  <brief_title>Proof-of-Concept Trial on Selective Removal of sFlt-1 in Pregnant Women With Preeclampsia Via Apheresis</brief_title>
  <acronym>SAVE</acronym>
  <official_title>Proof-of-Concept Trial on Selective Removal of the Antiangiogenic Factor Soluble Fms-like Tyrosine Kinase-1 (sFlt-1) in Pregnant Women With Preeclampsia Via Apheresis Utilizing the Flt-1 Adsorption Column</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Miltenyi Biomedicine GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cromsource</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Miltenyi Biomedicine GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical investigation is a medical device trial to examine the safety and efficacy of&#xD;
      TheraSorb sFlt-1 adsorber treatment of pregnant patients with preeclampsia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of AEs and SAEs in healthy volunteers until the 2 weeks follow-up (Phase 0)</measure>
    <time_frame>until 2 weeks post treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of AEs and SAEs in pregnant subjects and the fetus or infant until the 6 weeks post-delivery visit is reached (Phase A-B).</measure>
    <time_frame>until 6 weeks post delivery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 0: Determine changes of sFlt-1 levels.</measure>
    <time_frame>until 2 weeks post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 0: Complement activation levels pre-, during and post apheresis.</measure>
    <time_frame>Before, during and directly following the performance of the single apheresis treatment (1 day)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 0: Concentration of antibody leaching during an apheresis procedure</measure>
    <time_frame>During an apheresis procedure (1 day)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 0: Change of HAMA levels in pre- and post apheresis blood</measure>
    <time_frame>until 2 weeks post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 0: Evaluate blood pressure values</measure>
    <time_frame>until 2 weeks post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 0: Evaluate spot urine values</measure>
    <time_frame>until 2 weeks post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase A/B: Occurrence of SAEs in the one year follow-up period</measure>
    <time_frame>until end of FU, (1 year)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phases A/B: Evaluate antibody leaching in phase A.</measure>
    <time_frame>During the performance of the single apheresis treatment in Phase A (1 day) as well as pre and 3hrs post apheresis</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phases A and B: Evaluate maternal sFlt-1 levels.</measure>
    <time_frame>Constant measures throughout the trial until delivery (up to 19 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phases A/B: Evaluate the sFlt-1/PlGF ratio.</measure>
    <time_frame>Constant measures throughout the trial until delivery (up to 19 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phases A/B:Evaluate neonatal umbilical cord blood sFlt-1 levels at birth.</measure>
    <time_frame>at birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phases A/B: Determine HAMA levels</measure>
    <time_frame>until 6 week FU visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phases A/B: Time and method of delivery, and anesthesia administered</measure>
    <time_frame>at birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phases A and B: Determine the post-partum maternal and neonatal length of hospitalization.</measure>
    <time_frame>Following birth up to one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phases A/B: Evaluate standard markers of fetal development throughout pregnancy.</measure>
    <time_frame>From start of trial until delivery (up to 19 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phases A/B: Evaluate standard markers of neonatal development.</measure>
    <time_frame>Directly following delivery until end of FU (1 year)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">23</enrollment>
  <condition>Preeclampsia</condition>
  <arm_group>
    <arm_group_label>Phase 0 - healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 0 is an initial safety phase where subjects will undergo one single TheraSorb sFlt-1 adsorber apheresis procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase A - preeclampsia patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase A is a safety and dose-finding phase during which pregnant women diagnosed with preeclampsia will undergo one single TheraSorb sFlt-1 adsorber apheresis procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase B - preeclampsia patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase B is a safety and efficacy phase during which pregnant women diagnosed with preeclampsia will undergo TheraSorb sFlt-1 adsorber apheresis procedures up to twice weekly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TheraSorb sFlt-1 adsorber</intervention_name>
    <description>Removal of excessive sFlt-1 from the plasma of subjects/ patients with therapeutic apheresis.</description>
    <arm_group_label>Phase 0 - healthy volunteers</arm_group_label>
    <arm_group_label>Phase A - preeclampsia patients</arm_group_label>
    <arm_group_label>Phase B - preeclampsia patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Reduced criteria!&#xD;
&#xD;
        Phase 0&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 and ≤45 years;&#xD;
&#xD;
          -  Male or female;&#xD;
&#xD;
          -  Female subjects of childbearing potential must have a negative serum pregnancy test&#xD;
             result at screening and practice two reliable methods of contraception throughout the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Dysfunction of cerebral nervous system and/or heart disease;&#xD;
&#xD;
          -  History of preexisting chronic renal disease;&#xD;
&#xD;
          -  Treatment with ACE inhibitors;&#xD;
&#xD;
          -  Therapeutic full anticoagulation therapy prior to trial entry;&#xD;
&#xD;
          -  Liver abnormalities;&#xD;
&#xD;
          -  Clinically significant pulmonary edema and/or thrombocytopenia and/or anemia;&#xD;
&#xD;
          -  Active hepatitis B, C, or tuberculosis infection or HIV infection&#xD;
&#xD;
          -  Hypersensitivity to heparin and/or citrate;&#xD;
&#xD;
          -  Indications that prohibit transient anticoagulation using heparin and/or&#xD;
             ACD-A-solutions;&#xD;
&#xD;
          -  Known intolerance to extracorporeal procedures in general or towards one of the&#xD;
             individual excipients or towards other supporting agents;&#xD;
&#xD;
          -  Drug or alcohol abuse within the last 2 years;&#xD;
&#xD;
          -  Lack of compliance of subject;&#xD;
&#xD;
          -  History or diagnosis of severe periodontitis;&#xD;
&#xD;
        Phase A and B&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18 and ≤45 years ;&#xD;
&#xD;
          -  Pregnant woman with pre-term preeclampsia&#xD;
&#xD;
          -  sFlt-1/PlGF ratio ≥85 ;&#xD;
&#xD;
          -  sFlt-1 level of ≥ 8000pg/mL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Maternal exclusion criteria&#xD;
&#xD;
          -  History of cardiac impairments including uncontrolled arrhythmia, unstable angina,&#xD;
             decompensated congestive heart failure or valve disease;&#xD;
&#xD;
          -  History of preexisting chronic renal disease (CKD stage &gt;3a, eGFR ≤45ml/min/1.73m²);&#xD;
&#xD;
          -  Treatment with ACE inhibitors;&#xD;
&#xD;
          -  Therapeutic full anticoagulation therapy prior to trial entry;&#xD;
&#xD;
          -  Signs or history of clinically significant cerebral nervous system dysfunction;&#xD;
&#xD;
          -  History of clinically significant liver abnormalities;&#xD;
&#xD;
          -  Clinically significant pulmonary edema and/or thrombocytopenia and/or anemia;&#xD;
&#xD;
          -  Active hepatitis B, C, tuberculosis infection or HIV-positive status;&#xD;
&#xD;
          -  Any condition that the investigator deems a risk to the patient or fetus in completing&#xD;
             the trial;&#xD;
&#xD;
          -  Indications that prohibit transient anticoagulation using heparin and/or&#xD;
             ACD-A-solutions;&#xD;
&#xD;
          -  Drug or alcohol abuse within the last 2 years;&#xD;
&#xD;
          -  Lack of compliance of patient;&#xD;
&#xD;
          -  Known intolerance to extracorporeal procedures in general or to one of the excipients&#xD;
             or other supporting agents;&#xD;
&#xD;
          -  Hypersensitivity to heparin and/or citrate;&#xD;
&#xD;
          -  &lt; 30 0/7 weeks of gestation and abnormal CTG and/or abnormal Ductus venosus Doppler&#xD;
             flow,&#xD;
&#xD;
          -  ≥30 0/7 weeks of gestation and Doppler evidence of umbilical artery Absent or Reversed&#xD;
             End-Diastolic Velocity (AREDV);&#xD;
&#xD;
          -  Various Placental exclusion criteria;&#xD;
&#xD;
          -  Multiple pregnancy&#xD;
&#xD;
          -  History or diagnosis of severe periodontitis&#xD;
&#xD;
        Fetal exclusion criteria&#xD;
&#xD;
          -  Any known trisomy;&#xD;
&#xD;
          -  Amniotic fluid index &lt;5cm (greatest single pocket &lt;2cm);&#xD;
&#xD;
          -  Estimated fetal weight &lt;3rd percentile for gestational age;&#xD;
&#xD;
          -  Fetus which are at high risk of heart disease;&#xD;
&#xD;
          -  Fetus with congenital heart defect;&#xD;
&#xD;
          -  Fetal signs of bleeding;&#xD;
&#xD;
          -  Hydrops fetalis;&#xD;
&#xD;
          -  Pathological fetal Doppler flow of the ductus venosus (absent A-wave in two&#xD;
             measurements);&#xD;
&#xD;
          -  Evidence of severe fetal malformations;&#xD;
&#xD;
          -  Known infection of fetus;&#xD;
&#xD;
          -  Known severe anemia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jörg Liebmann, PhD</last_name>
    <email>joergli@miltenyi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsklinikum Köln</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Henning Hagmann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Holger Stepan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cambridge Clinical Trials Unit, Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Janye, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manu Vatish, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 19, 2016</study_first_submitted>
  <study_first_submitted_qc>October 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2016</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>apheresis</keyword>
  <keyword>pregnancy</keyword>
  <keyword>pre-eclampsia</keyword>
  <keyword>PE</keyword>
  <keyword>sFlt-1</keyword>
  <keyword>Pre-term</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

